 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

As many as 3.3 lakh shares of Aarti Drugs were traded on the exchanges till afternoon

Aarti Drugs jumps 4%, partly recoups last two days’ losses

Axis Securities is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 665 in its research report dated July 25 2023.

Buy Aarti Drugs; target of Rs 665: Axis Securities

The sharp reaction in Aarti Drugs was also fueled by strong volumes as they were significantly higher than the one-month daily traded average.

Aarti Drugs spikes 18% to hit 52-week high on buyback offer with sharp premium

Aarti Drugs Consolidated June 2023 Net Sales at Rs 661.11 crore, up 6.29% Y-o-Y

Aarti Drugs Standalone June 2023 Net Sales at Rs 591.63 crore, up 7.33% Y-o-Y

Aarti Drugs Consolidated March 2023 Net Sales at Rs 742.41 crore, up 6.93% Y-o-Y

Aarti Drugs Consolidated December 2022 Net Sales at Rs 663.96 crore, up 4.59% Y-o-Y

Aarti Drugs Standalone December 2022 Net Sales at Rs 625.53 crore, up 5.45% Y-o-Y

Aarti Drugs Standalone September 2022 Net Sales at Rs 624.83 crore, up 22.35% Y-o-Y

Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The firm operates through the Out of India, and India geographical segments. Its products include active pharmaceutical ingredient, specialty chemicals, pharma intermediate, products under development, and product under pipeline. The company was founded on September 28, 1984 and is headquartered in Mumbai, India.

Watchers	87
52-Wk Low	313.90
52-Wk High	645.75

Market Cap	53.61B
Volume (M)	105,721.00
52-Wk High	645.75
52-Wk Low	313.90

AARTIDRUGS.NSE Aarti Drugs Ltd.

About

Feed

News

Fundamentals